Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review

Ming Shyen Yen; Jen Ruei Chen; Peng Hui Wang; Kuo Chang Wen; Yi Jen Chen; Heung Tat Ng; Yen Hou Chang; Yi Chang; Hsiang Tai Chao; Kuan Chong Chao; Chi Mu Chuang; Chi Hong Ho; Huann Cheng Horng; Chen Yu Huang; Ling Yu Jiang; Chia Hao Liu; Hsin Yang Li; Pi Lin Sun; Hua Hsi Wu; Fong Yuan Ju; Chih Ping Tsai; Wen Hsun Chang; Yen Mei Hsu; Shu Yun Huang; Na Rong Lee; Chih Yao Chen; Wen Chun Chang; Chii Hou Chen; Ruey Jian Chen; Song Nan Chow; Yih Ron Lien; Bor Ching Sheu; Pao Ling Torng; Lin Hung Wei; Men Luh Yen; Wen Ling Lee; Kuan Chin Wang; Chih Long Chang; Chih Ping Chen; Tze Chien Chen; Jian Pei Huang; Ming Chao Huang; Yeou Lih Wang; Cheng Chang Chang; Jah Yao Liu; Her Young Su; Yu Chi Wang; Mu Hsien Yu; Wei Min Liu; Hung Cheng Lai; the Taiwan Association of Gynecology Systematic Review Group; Ching-Hui Chen

doi:10.1016/j.tjog.2016.07.001

Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review

Ming Shyen Yen, Jen Ruei Chen, Peng Hui Wang, Kuo Chang Wen, Yi Jen Chen, Heung Tat Ng, Yen Hou Chang, Yi Chang, Hsiang Tai Chao, Kuan Chong Chao, Chi Mu Chuang, Chi Hong Ho, Huann Cheng Horng, Chen Yu Huang, Ling Yu Jiang, Chia Hao Liu, Hsin Yang Li, Pi Lin Sun, Hua Hsi Wu, Fong Yuan JuChih Ping Tsai, Wen Hsun Chang, Yen Mei Hsu, Shu Yun Huang, Na Rong Lee, Chih Yao Chen, Wen Chun Chang, Chii Hou Chen, Ruey Jian Chen, Song Nan Chow, Yih Ron Lien, Bor Ching Sheu, Pao Ling Torng, Lin Hung Wei, Men Luh Yen, Wen Ling Lee, Kuan Chin Wang, Chih Long Chang, Chih Ping Chen, Tze Chien Chen, Jian Pei Huang, Ming Chao Huang, Yeou Lih Wang, Cheng Chang Chang, Jah Yao Liu, Her Young Su, Yu Chi Wang, Mu Hsien Yu, Wei Min Liu, Hung Cheng Lai, the Taiwan Association of Gynecology Systematic Review Group, Ching-Hui Chen

研究成果: 雜誌貢獻 › 回顧型文獻 › 同行評審

13 引文斯高帕斯（Scopus）

摘要

Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of diseases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and highly divergent genetic aberration. Uterine sarcomas are often classified into four distinct subtypes, including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine endometrial stromal sarcoma, and undifferentiated uterine sarcoma. Currently, evidence from tumor biology found that these tumors showed alternation and/or mutation of genomes and the intracellular signal pathway. In addition, some preclinical studies showed promising results for targeting receptor tyrosine kinase signaling, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway, various kinds of growth factor pathways, Wnt/beta-catenin signaling pathway, transforming growth factor β/bone morphogenetic protein signal pathway, aurora kinase A, MDM2 proto-oncogene, histone deacetylases, sex hormone receptors, certain types of oncoproteins, and/or loss of tumor suppressor genes. The current review is attempted to summarize the recurrent advance of targeted therapy for uterine sarcomas.

原文	英語
頁（從 - 到）	625-634
頁數	10
期刊	Taiwanese Journal of Obstetrics and Gynecology
卷	55
發行號	5
DOIs	https://doi.org/10.1016/j.tjog.2016.07.001
出版狀態	已發佈 - 10月 1 2016

ASJC Scopus subject areas

婦產科

存取文件

10.1016/j.tjog.2016.07.001

其它文件與鏈接

引用此

Yen, M. S., Chen, J. R., Wang, P. H., Wen, K. C., Chen, Y. J., Ng, H. T., Chang, Y. H., Chang, Y., Chao, H. T., Chao, K. C., Chuang, C. M., Ho, C. H., Horng, H. C., Huang, C. Y., Jiang, L. Y., Liu, C. H., Li, H. Y., Sun, P. L., Wu, H. H., ... Chen, C.-H. (2016). Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review. Taiwanese Journal of Obstetrics and Gynecology, 55(5), 625-634. https://doi.org/10.1016/j.tjog.2016.07.001

Yen, MS, Chen, JR, Wang, PH, Wen, KC, Chen, YJ, Ng, HT, Chang, YH, Chang, Y, Chao, HT, Chao, KC, Chuang, CM, Ho, CH, Horng, HC, Huang, CY, Jiang, LY, Liu, CH, Li, HY, Sun, PL, Wu, HH, Ju, FY, Tsai, CP, Chang, WH, Hsu, YM, Huang, SY, Lee, NR, Chen, CY, Chang, WC, Chen, CH, Chen, RJ, Chow, SN, Lien, YR, Sheu, BC, Torng, PL, Wei, LH, Yen, ML, Lee, WL, Wang, KC, Chang, CL, Chen, CP, Chen, TC, Huang, JP, Huang, MC, Wang, YL, Chang, CC, Liu, JY, Su, HY, Wang, YC, Yu, MH, Liu, WM, Lai, HC, the Taiwan Association of Gynecology Systematic Review Group & Chen, C-H 2016, 'Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review', Taiwanese Journal of Obstetrics and Gynecology, 卷 55, 編號 5, 頁 625-634. https://doi.org/10.1016/j.tjog.2016.07.001

@article{0c3580f58fa442bf9e890891ae9d9c80,

title = "Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review",

abstract = "Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of diseases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and highly divergent genetic aberration. Uterine sarcomas are often classified into four distinct subtypes, including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine endometrial stromal sarcoma, and undifferentiated uterine sarcoma. Currently, evidence from tumor biology found that these tumors showed alternation and/or mutation of genomes and the intracellular signal pathway. In addition, some preclinical studies showed promising results for targeting receptor tyrosine kinase signaling, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway, various kinds of growth factor pathways, Wnt/beta-catenin signaling pathway, transforming growth factor β/bone morphogenetic protein signal pathway, aurora kinase A, MDM2 proto-oncogene, histone deacetylases, sex hormone receptors, certain types of oncoproteins, and/or loss of tumor suppressor genes. The current review is attempted to summarize the recurrent advance of targeted therapy for uterine sarcomas.",

keywords = "targeted therapy, uterine endometrial stromal sarcoma, uterine leiomyosarcoma, uterine sarcoma",

author = "Yen, {Ming Shyen} and Chen, {Jen Ruei} and Wang, {Peng Hui} and Wen, {Kuo Chang} and Chen, {Yi Jen} and Ng, {Heung Tat} and Chang, {Yen Hou} and Yi Chang and Chao, {Hsiang Tai} and Chao, {Kuan Chong} and Chuang, {Chi Mu} and Ho, {Chi Hong} and Horng, {Huann Cheng} and Huang, {Chen Yu} and Jiang, {Ling Yu} and Liu, {Chia Hao} and Li, {Hsin Yang} and Sun, {Pi Lin} and Wu, {Hua Hsi} and Ju, {Fong Yuan} and Tsai, {Chih Ping} and Chang, {Wen Hsun} and Hsu, {Yen Mei} and Huang, {Shu Yun} and Lee, {Na Rong} and Chen, {Chih Yao} and Chang, {Wen Chun} and Chen, {Chii Hou} and Chen, {Ruey Jian} and Chow, {Song Nan} and Lien, {Yih Ron} and Sheu, {Bor Ching} and Torng, {Pao Ling} and Wei, {Lin Hung} and Yen, {Men Luh} and Lee, {Wen Ling} and Wang, {Kuan Chin} and Chang, {Chih Long} and Chen, {Chih Ping} and Chen, {Tze Chien} and Huang, {Jian Pei} and Huang, {Ming Chao} and Wang, {Yeou Lih} and Chang, {Cheng Chang} and Liu, {Jah Yao} and Su, {Her Young} and Wang, {Yu Chi} and Yu, {Mu Hsien} and Liu, {Wei Min} and Lai, {Hung Cheng} and {the Taiwan Association of Gynecology Systematic Review Group} and Ching-Hui Chen",

note = "Publisher Copyright: {\textcopyright} 2016",

year = "2016",

month = oct,

day = "1",

doi = "10.1016/j.tjog.2016.07.001",

language = "English",

volume = "55",

pages = "625--634",

journal = "Taiwanese Journal of Obstetrics and Gynecology",

issn = "1028-4559",

publisher = "臺灣婦產科醫學會",

number = "5",

}

TY - JOUR

T1 - Uterine sarcoma part III—Targeted therapy

T2 - The Taiwan Association of Gynecology (TAG) systematic review

AU - Yen, Ming Shyen

AU - Chen, Jen Ruei

AU - Wang, Peng Hui

AU - Wen, Kuo Chang

AU - Chen, Yi Jen

AU - Ng, Heung Tat

AU - Chang, Yen Hou

AU - Chang, Yi

AU - Chao, Hsiang Tai

AU - Chao, Kuan Chong

AU - Chuang, Chi Mu

AU - Ho, Chi Hong

AU - Horng, Huann Cheng

AU - Huang, Chen Yu

AU - Jiang, Ling Yu

AU - Liu, Chia Hao

AU - Li, Hsin Yang

AU - Sun, Pi Lin

AU - Wu, Hua Hsi

AU - Ju, Fong Yuan

AU - Tsai, Chih Ping

AU - Chang, Wen Hsun

AU - Hsu, Yen Mei

AU - Huang, Shu Yun

AU - Lee, Na Rong

AU - Chen, Chih Yao

AU - Chang, Wen Chun

AU - Chen, Chii Hou

AU - Chen, Ruey Jian

AU - Chow, Song Nan

AU - Lien, Yih Ron

AU - Sheu, Bor Ching

AU - Torng, Pao Ling

AU - Wei, Lin Hung

AU - Yen, Men Luh

AU - Lee, Wen Ling

AU - Wang, Kuan Chin

AU - Chang, Chih Long

AU - Chen, Chih Ping

AU - Chen, Tze Chien

AU - Huang, Jian Pei

AU - Huang, Ming Chao

AU - Wang, Yeou Lih

AU - Chang, Cheng Chang

AU - Liu, Jah Yao

AU - Su, Her Young

AU - Wang, Yu Chi

AU - Yu, Mu Hsien

AU - Liu, Wei Min

AU - Lai, Hung Cheng

AU - the Taiwan Association of Gynecology Systematic Review Group

AU - Chen, Ching-Hui

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of diseases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and highly divergent genetic aberration. Uterine sarcomas are often classified into four distinct subtypes, including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine endometrial stromal sarcoma, and undifferentiated uterine sarcoma. Currently, evidence from tumor biology found that these tumors showed alternation and/or mutation of genomes and the intracellular signal pathway. In addition, some preclinical studies showed promising results for targeting receptor tyrosine kinase signaling, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway, various kinds of growth factor pathways, Wnt/beta-catenin signaling pathway, transforming growth factor β/bone morphogenetic protein signal pathway, aurora kinase A, MDM2 proto-oncogene, histone deacetylases, sex hormone receptors, certain types of oncoproteins, and/or loss of tumor suppressor genes. The current review is attempted to summarize the recurrent advance of targeted therapy for uterine sarcomas.

AB - Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of diseases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and highly divergent genetic aberration. Uterine sarcomas are often classified into four distinct subtypes, including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine endometrial stromal sarcoma, and undifferentiated uterine sarcoma. Currently, evidence from tumor biology found that these tumors showed alternation and/or mutation of genomes and the intracellular signal pathway. In addition, some preclinical studies showed promising results for targeting receptor tyrosine kinase signaling, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway, various kinds of growth factor pathways, Wnt/beta-catenin signaling pathway, transforming growth factor β/bone morphogenetic protein signal pathway, aurora kinase A, MDM2 proto-oncogene, histone deacetylases, sex hormone receptors, certain types of oncoproteins, and/or loss of tumor suppressor genes. The current review is attempted to summarize the recurrent advance of targeted therapy for uterine sarcomas.

KW - targeted therapy

KW - uterine endometrial stromal sarcoma

KW - uterine leiomyosarcoma

KW - uterine sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84992378741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992378741&partnerID=8YFLogxK

U2 - 10.1016/j.tjog.2016.07.001

DO - 10.1016/j.tjog.2016.07.001

M3 - Review article

C2 - 27751406

AN - SCOPUS:84992378741

SN - 1028-4559

VL - 55

SP - 625

EP - 634

JO - Taiwanese Journal of Obstetrics and Gynecology

JF - Taiwanese Journal of Obstetrics and Gynecology

IS - 5

ER -

Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review

摘要

ASJC Scopus subject areas

存取文件

其它文件與鏈接

指紋

引用此